[Analysis of the efficacy of half-dose venetoclax combined with reduced-dose HA regimen in the induction therapy of acute myeloid leukemia]
{{output}}
We retrospectively analyzed clinical data on newly diagnosed acute myeloid leukemia (AML) patients who received HAV treatment between June 2020 and April 2023. The HAV regimen includes venetoclax at 100 mg on day 0 and 200 mg from day 1 to 14, administered ora... ...
